drugset
drugset / Trial / NCT03384186

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

NCT03384186 ↗

Phase 1 Completed 14 enrolled Alexion Pharmaceuticals, Inc. Achillion, a wholly owned subsidiary of Alexion · collab
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study was to evaluate and compare the plasma pharmacokinetic profiles of ACH-0144471 (danicopan) in healthy participants after administration of single oral doses of modified release prototype formulations.

Timeline

Start
2017-12-01
Primary completion
2018-03-21
Completion
2018-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Danicopan Small molecule 400 mg Oral
Subject Danicopan Small molecule 800 mg Oral

Indications

No indication recorded.